Abstract 93P
Background
Urothelial carcinoma (UC) is a prevalent malignancy in the urinary system, which consists of approximately 82% of bladder cancer and 18% upper tract urothelial carcinomas (UTUCs) in China. The diagnosis of UC poses significant challenges due to the invasiveness of cystoscopy and the limited sensitivity of cytology. Therefore, there is a pressing clinical demand for developing more sensitive and non-invasive diagnostic techniques to complement the existing approaches.
Methods
In this study, we conducted a comprehensive analysis utilizing methylation data from The Cancer Genome Atlas (TCGA), the Gene Expression Omnibus (GEO) database, and a cohort from Renji Hospital. These datasets served as discovery cohorts for the identification of UC-specific methylation markers. Urine samples from 180 cases were collected as a training cohort. Quantitative methylation-specific PCR was performed on these samples, followed by logistic regression for constructing a diagnostic model. The model's performance was further validated in a prospective cohort comprising 508 cases.
Results
Our analysis of the discovery cohort identified three significant methylation markers. UriMee, a diagnostic model, based on two urine-based methylation markers in the training cohort (65 UC cases vs. 115 non-UC cases), exhibited remarkable performance with an area under the curve (AUC) of 0.96. In the independent validation cohort (154 UC cases vs. 354 non-UC cases), UriMee demonstrated a sensitivity of 91% and a specificity of 93% (AUC=0.94). Notably, for early-stage (Ta-1) cases, the sensitivity reached 87%. Moreover, a significant correlation was observed between the UriMee detection values and tumor grade, with an 81% sensitivity for detecting low grade cases. UriMee also demonstrated high accuracy, reaching 91%, in diagnosing UTUCs.
Conclusions
UriMee holds significant promise as a non-invasive urine-based testing method, which has the potential to greatly enhance the early diagnosis of UC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1792P - Molecular characterization from IMfirst: Atezolizumab plus chemotherapy in extensive-stage small cell lung cancer (ES-SCLC) in Spain
Presenter: Manuel Cobo Dols
Session: Poster session 07
1793P - Treatment and outcomes of limited disease small cell lung cancer (LD-SCLC) in the Canadian small cell lung cancer database (CASCADE)
Presenter: Sara Moore
Session: Poster session 07
1794P - Deciphering ERBB2-driven mechanisms that regulate tumor immune evasion and metastasis in SCLC
Presenter: Lydia Meder
Session: Poster session 07
1795P - Consolidation serplulimab following concurrent hypofractionated chemoradiotherapy for limited-stage SCLC: Preliminary analysis of phase II ASTRUM-LC01 study
Presenter: Yuqi Wu
Session: Poster session 07
1796P - Smoking-related genomic mutation patterns in patients with small cell lung cancer treated in ASTRUM-005 study
Presenter: Ying Cheng
Session: Poster session 07
1798P - Relapsed and refractory systemic therapy real-world outcomes in the Canadian small cell lung cancer database (CASCADE)
Presenter: Sara Moore
Session: Poster session 07
1799P - Efficacy and safety of integrating consolidative thoracic radiotherapy with immunochemotherapy in ES-SCLC: A real-world retrospective analysis
Presenter: Qi Zhang
Session: Poster session 07
1800P - Breaking chemo-immunotherapy resistance in SCLC-patient derived tumor with novel DDRi combinations
Presenter: Carminia Della Corte
Session: Poster session 07
1801P - Expression analysis of Fuc-GM1 ganglioside in first-line therapy for extensive-stage small cell lung cancer (ES-SCLC) with BMS-986012, nivolumab, and carboplatin-etoposide
Presenter: Kenneth O'Byrne
Session: Poster session 07